Breakthrough COVID-19 Vaccine Shows Robust Protection Against Variants

A New Hope in the Fight Against Coronaviruses

A groundbreaking development in the field of vaccine research has emerged from the collaboration between the Centenary Institute and the University of Sydney. Researchers have unveiled a promising new candidate for a COVID-19 vaccine, which shows strong potential to protect against both current and future coronavirus variants. This innovative approach targets shared features among various coronaviruses, aiming to provide broader and longer-lasting immunity as the virus continues to evolve.

As Australia experiences ongoing circulation of the virus during winter, with new omicron subvariants like XBB.1.5 contributing to increased cases and hospitalizations, the need for effective vaccines becomes even more critical. The Australian Government's National Notifiable Diseases Surveillance System has recorded over 115,000 cases for 2025 alone, highlighting the urgency of this research.

The study, published in the journal npj Vaccines, details the effectiveness of a vaccine candidate called CoVEXS5. In laboratory tests, this vaccine protected mice from multiple coronaviruses, including the highly immune-evasive omicron XBB.1.5 variant and SARS-CoV-1, which was responsible for the 2002–2004 SARS outbreak. The results were remarkable, with CoVEXS5 reducing virus levels in the lungs of infected mice by approximately 99.9% compared to unvaccinated controls.

One of the key aspects of CoVEXS5 is its ability to trigger high levels of virus-blocking antibodies and activate special immune T-cells in the lungs. These T-cells play a crucial role in defending against respiratory viruses, offering a robust defense mechanism. The vaccine features a unique version of the spike protein, which fuses protein elements from several coronaviruses into a single structure. This fusion allows the immune system to recognize and respond to a broader range of virus types, rather than just one specific strain.

Dr. Claudio Counoupas, co-lead study author and researcher at the Centenary Institute's Center for Infection & Immunity, emphasized the significance of this approach. "By combining parts of multiple coronaviruses, we've created a vaccine that can better prepare the body to fight off both current and future threats," he said.

Elizabeth Chan, a Ph.D. student at the Centenary Institute and the University of Sydney, added that the findings highlight the potential for a next-generation COVID-19 vaccine that could work across different variants. "The immune response we saw in the laboratory was both strong and broad. It's exciting to think that this approach could help future-proof vaccines against ongoing changes in the virus," she said.

In addition to its innovative design, CoVEXS5 includes Sepivac SWE, an open-access adjuvant that enhances the immune response. This adjuvant offers practical advantages for vaccine manufacturing and global distribution. Professor Jamie Triccas, senior study author and Deputy Director of the Sydney Infectious Diseases Institute at the University of Sydney, noted the importance of this feature. "Sepivac SWE is not only effective, but because it's open-access, it can be used by manufacturers around the world without licensing barriers or high costs," he said.

This advantage is particularly significant for global vaccine equity, especially in low and middle-income countries where access and cost are critical concerns. The research team is now focused on advancing the vaccine candidate through further development and testing, with the goal of bringing this innovative solution to the public.

The study, titled "An adjuvanted chimeric spike antigen boosts lung-resident memory T-cells and induces pan-sarbecovirus protective immunity," provides valuable insights into the future of vaccine development. As the world continues to face the challenges posed by evolving coronaviruses, innovations like CoVEXS5 offer a beacon of hope for more effective and accessible protection.